ContraFect Corporation to Present at 12th Annual BIO Investor Forum

Bio Investor Forum to Be Held October 8-9 in San Francisco, Calif.

YONKERS, NY -- (Marketwired) -- 10/01/13 -- ContraFect Corporation announced that Dr. Robert Nowinski, the company's founder and chief executive officer, and Julia P. Gregory, the company's executive vice president and chief financial officer, will be presenting at the 12th Annual BIO Investor Forum. Hosted by the Biotechnology Industry Organization (BIO), the 12th Annual BIO Investor Forum features leading private and emerging public companies. The meeting will take place October 8-9 at the Palace Hotel in San Francisco, Calif. Dr. Nowinski and Ms. Gregory will discuss ContraFect's novel approach to drug resistant Staph infections and clinical plans for its lead product, CF-301. The Company's presentation will take place on Tuesday, October 8th at 11:00 am PDT.

About the Bio Investor Forum

The 12th Annual BIO Investor Forum is an international investor conference focused on private and emerging public biotech companies. Because our mission is to support industry-wide success, we present a broad and unbiased view of investment opportunities. In addition, the BIO Investor Forum draws business development executives from leading global pharmaceutical and established biotechnology companies.

About ContraFect

ContraFect Corporation is a clinical-stage biotechnology company focused on development and commercialization of products for life threatening infectious diseases, particularly those used in hospital-based markets. ContraFect's initial products include new agents to treat diseases such as MRSA (drug-resistant staphylococcus bacteria) and influenza. Its scientific strategy focuses on the use of combination therapies, where it believes that the company's products will overcome high rates of mutation and resistance observed in microbes.

Safe Harbor Statement

This release contains forward-looking statements, and any statements other than statements of historical facts could be deemed to be forward-looking statements. These forward-looking statements include, among other things, statements regarding future events that involve risks and uncertainties. These statements are based on management's current expectations and actual results and future events may differ materially due to risks and uncertainties, including those associated with our ability to obtain additional funds, obtain and maintain all necessary patents and licenses, meet applicable regulatory standards and receive required regulatory approvals, manufacture or commercialize our products at reasonable costs and compete with other products and market our products in a profitable manner. We assume no obligation to update or supplement any forward-looking statements whether as a result of new information, future events or otherwise.

For more information, contact:

Barry Kappel, Ph.D., MBA
VP Business Development
Tel: 914-207-2300
E-Mail: Email Contact
or visit:

Source: ContraFect Corporation